Benzinga – During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy. Here’s a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga’s Analyst Stock Ratings.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Gilead Sciences, Inc. (NASDAQ: GILD)
- Dividend Yield: 3.74%
- RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and cut the price target from $87 to $86 on March 6, 2023. This analyst has an accuracy rate of 76%.
- SVB Leerink analyst David Risinger maintained a Market Perform rating and boosted the price target from $81 to $91 on Feb. 3, 2023. This analyst has an accuracy rate of 75%.
- Recent News: Kite, a Gilead Science company, announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study.
Amgen Inc. (NASDAQ: AMGN)
- Dividend Yield: 3.57%
- SVB Leerink analyst David Risinger maintained a Market Perform rating and cut the price target from $282 to $267 on Feb. 2, 2023. This analyst has an accuracy rate of 75%.
- Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and cut the price target from $285 to $275 on Feb. 1, 2023. This analyst has an accuracy rate of 66%.
- Recent News: In a complaint filed in Manhattan federal court, a Detroit-based pension fund said Amgen concealed the dispute over its international tax strategy between July 2020 and April 2022 and had its investors wait for too long on disclosing taxes and penalties bill of $10.7 billion.
Baxter International Inc. (NYSE: BAX)
- Dividend Yield: 3.04%
- Citigroup analyst Joanne Wuensch maintained a Neutral rating and cut the price target from $58 to $44 on Feb. 13, 2023. This analyst has an accuracy rate of 79%.
- Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and slashed the price target from $52 to $43 on Feb. 10, 2023. This analyst has an accuracy rate of 77%.
- Recent News: Baxter International reported worse-than-expected Q4 adjusted EPS results and issued Q1 and FY23 adjusted EPS guidance below estimates.
Read More: Around $32M Bet On Southwest Gas? Check Out These 3 Stocks Insiders Are Buying
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
